A Phase I randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and immunogenicity of the GSK Biologicals herpes zoster vaccine, gE/AS01B, when administered in 3 doses versus 2 doses and versus placebo in autologous hemat
|Effective start/end date||2/6/09 → 8/21/12|
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.